Debu Tripathy

University of Texas Southwestern Medical Center, United States of America

Any competing interests declared are displayed with individual evaluations.

Faculty Member: Oncology > Breast Diseases: Benign & Malignant (since 11 January 2006)

All recent recommendations

• 3.0
  Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.
  Recommended by Debu Tripathy
  
• 6.4
  Weekly paclitaxel in the adjuvant treatment of breast cancer.
  Recommended by Debu Tripathy, Generosa Grana
  
• 6.0
  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.
  Recommended by Debu Tripathy
  
• 3.0
  HER2 and response to paclitaxel in node-positive breast cancer.
  Recommended by Debu Tripathy
  
• 6.0
  Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial.
  Recommended by Debu Tripathy
  
• 6.6
  Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
  Recommended by Debu Tripathy, Daniel Vorobiof, Nicola Normanno
  
• 3.0
  Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342.
  Recommended by Debu Tripathy
  
• 3.0
  Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide.
  Recommended by Debu Tripathy
  
• 3.0
  Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?
  Recommended by Debu Tripathy
  
• 3.0
  Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
  Recommended by Debu Tripathy